AspenBio Pharma Reports Second Quarter 20...(ned to aid in super-ovulation forembryo ...)

Date:8/20/2007

ned to aid in super-ovulation for embryo transfer in dairy and beef cows throughout the world. It will compete in a niche market comprised of a "small easy to reach" group of approximately 300 to 400 centers in the world that act as super-ovulation and embryo transfer (ET) locations. While the worldwide bovine FSH market is estimated to be between $15 million and $20 million annually, AspenBio believes BoviPure FSH could dominate this market due to the substantial labor savings, simplicity, and convenience of this one-dose drug. AspenBio also believes these many benefits will stimulate market growth and allow for premium pricing over conventional animal-derived FSH drugs. The current conventional treatment in the United States involves an eight-dose treatment professionally administered over 4 days at 12 hour intervals, with an $80 average total drug cost.

Additional research studies conducted over the last several months on both of these drugs continue to demonstrate their cost effectiveness in enhancing the reproduction process and maintaining improved pregnancy rates. If successfully approved by FDA, these products will be the only bovine LH \ FSH products in the US animal market with an FDA approval.

StayBred: Positive development activities continue on AspenBio's largest market potential, single-chain reproduction-enhancing drug, StayBred (a/k/a BoviPure LH an LH analog for cows). Recent development work on StayBred BoviPure LH has provided product improvements designed to lower production costs of this important new drug. The company continues to test additional potential uses of BoviPure LH, which it believes will further help increase pregnancy rates in dairy cows and potentially expand the total annual market potential beyond original estimates of $200 million.

AspenBio continues to receive strong market interest and has begun preliminary discussions with potential international licensing and/or partners to support FDA approval, distributi
'/>"/>

SOURCE AspenBio Pharma, Inc. Copyright©2007 PR Newswire.

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango